A 62-year-old man was diagnosed with the onset of tuberculosis (Tb) from a pulmonary latent tuberculosis infection (LTBI) during triple therapy with pegylated interferon α2a, ribavirin, and telaprevir for a chronic hepatitis C infection in 2013 before interferon (IFN)-free anti-viral therapy was introduced in Japan. A liver biopsy before IFN treatment revealed the presence of epithelioid cell granulomas (ECGs). IFN may also be employed for chronic hepatitis B infection and malignant tumors, thus, special attention must be paid to the development of Tb from a LTBI when ECGs are observed before treatment. It is also necessary to review the significance of the liver biopsy.
Introduction
Interferon (IFN) is a class of proteins produced by virusinfected cells that exerts anti-proliferative activity against viruses and anti-tumor effects. In Japan, it had previously been used as anti-viral therapy for chronic hepatitis C (CHC) infection, however, treatment has recently shifted to oral direct-acting antivirals (DAAs). However, IFN is currently the first-line drug for chronic hepatitis B (CHB) infection in young patients and is also occasionally used for treating tumors such as multiple myeloma, renal cell carcinoma, and malignant melanoma. It is known that depression, pancytopenia, interstitial pneumonitis, and the induction of autoimmune disease are adverse effects of IFN therapy, and infectious diseases may be induced when cellular immunity is perturbed.
We herein report a case that was diagnosed with the onset of tuberculosis (Tb) from a pulmonary latent tuberculosis infection (LTBI) during combination therapy with telaprevir (TVR), pegylated-IFNα2a (PEG-IFNα2a), and ribavirin (RBV). After pulmonary infiltrative shadows were detected in the lungs and an IFN-γ release assay (IGRA) was found to be positive, the patient was treated successfully with antiTb agents.
Case Report
A 62-year-old man, who was taking candesartan 8 mg and amlodipine 10 mg for hypertension, received PEGIFNα2a and RBV therapy for CHC infection at another hospital in 2006. The patient was negative for hepatitis C virus (HCV), but became positive. He was referred to our hospital in June 2013 for the introduction of triple therapy (PEGIFNα2a + TVR + RBV).
A physical examination on admission revealed the following: height, 169 cm; body weight, 66 kg; body temperature, 36.1 ; pulse, 68 bpm; blood pressure, 113/63 mmHg; chest, no abnormal sounds on auscultation; abdomen, soft and flat; liver, not palpable; and palmar erythema, absent. (Table 1) . Interleukin-28 (IL-28) was found to be of the homozygous type upon examination before admission to our hospital.
The image diagnosis was as follows: abdominal ultrasound (AUS) and computed tomography (CT) revealed a chronic liver injury pattern but no hepatic tumors, splenomegaly, or lymph node swelling.
The patient's clinical course was as follows: a liver biopsy was carried out on day 2 after admission to our hospital. Liver histology revealed chronic active hepatitis corresponding to F2A2 by the New Inuyama Classification. Furthermore, because irregular regeneration (IR) was observed in addition to F2 fibrosis (Fig. 1A) , the patient was considered to be at an increased risk for carcinogenesis. Thus, triple therapy was started on day 4 after informed consent was obtained from the patient. Two well-delineated epithelioid cell granulomas (ECGs) were detected in the liver parenchyma (Fig. 1B, C) .
The following day after the initiation of treatment, the patient experienced pyrexia, headache, and anorexia, thus, drip infusion was administered daily thereafter. Even on day 8, his oral intake was poor and nutrition was mostly dependent on drip infusion. The patient's white blood cell count (WBC) was decreased to 2,590/μL (slightly decreased, normal range, 4,000-8,000); granulocytes, 1,370/μL; lymphocytes, 890/μL (normal range, 800-3,200); and mild renal dysfunction with a blood urea nitrogen (BUN) concentration of 12 mg/dL and creatinine (CRE) of 1.14 mg/dL (slightly increased, normal range, 0.8-1.1) were observed. Therefore, the second PEG-IFNα2a administration was postponed to day 12 and the dose was reduced to 50 μg. Since the patient only suffered from a headache, which was considered to be a subjective symptom, he was discharged from the hospital on day 27.
At the outpatient clinic, PEG-IFNα2a was continued at a reduced dose of 50 μg and HCV-ribonucleic acid (HCV-RNA) became negative from week 4 of treatment. However, a low-grade fever persisted since the introduction of treatment. On day 55, the seventh administration was finished, and there were no symptoms, such as a cough, other than the low-grade fever and a headache. On day 62, a chest Xray and CT were carried out for exploration of the cause of the low-grade fever, and scattered infiltrative shadows that were not observed on admission were detected in the right upper lung (Fig. 2) .
A rapid sputum test according to the Gaffky scale and a subsequent polymerase chain reaction (PCR) analysis revealed no abnormal findings (Table 2 ), but IGRA was positive. The WBC on the same day was normal at 6,180/μL, however, the lymphocytes were decreased to 670/μL (normal range, 800-3,200).
According to these findings, Tb was diagnosed and IFN was terminated. Rifampicin (RFP), ethambutol (EB), and isoniazid (INH) were introduced, and pyrexia disappeared. On day 77, a chest X-ray showed rapid disappearance of the pulmonary infiltrative shadows. HCV-RNA remained negative thereafter and a sustained virologic response (SVR) was achieved (Fig. 3) .
Discussion
IFN belongs to a class of proteins produced by virusinfected cells and plays roles in the suppression of viral rep- lication, antitumor effects, and immune activation. In Japan, it had previously been employed as anti-viral therapy for CHC infection, however, treatment has recently shifted to oral DAAs (1, 2). On the other hand, a year-long administration of PEG-IFN decreases hepatic B surface antigen (HBs-Ag) and achieves a drug-free status (3), thus, it is the first-line therapy for CHB infection. Moreover, it is occasionally used as chemotherapy for renal cell carcinoma (4), multiple myeloma, and malignant melanoma.
When CHC infection is left untreated, half of these cases develop liver cirrhosis, as well as hepatocellular carcinoma (HCC) from chronic hepatitis (1). Therefore, various antiviral therapies have been employed, and triple therapy with PEG-IFN, RBV, and DAAs was shown to achieve SVR in 84% of refractory serotype 1 cases (5). Furthermore, a combination of oral DAAs achieved SVR in nearly 100% of such cases (1, 2) .
Because the present case demonstrated recurrence of serotype 1 CHC with a high-titer viral load before the introduction of DAAs in Japan, a combination of PEG-IFNα2a, TVR, and RBV was administered after the patient's informed consent was obtained. Although it is known that this therapy is associated with adverse effects such as induction of skin lesions (6), the present case developed no such complications. However, despite the long clinical course after the introduction of IFN, pyrexia persisted and a chest Xray revealed infiltrative shadows in the right lung. Since IGRA was positive, Tb was diagnosed and anti-Tb agents were administered after the termination of PEG-IFNα2a therapy.
IGRA is a test to measure γ-IFN produced by lymphocytes that are stimulated by Tb-specific antigens such as secretory antigenic target 6 (ESAT-6) and culture filtrate protein 10 (CFP-10). Since the test is not influenced by Bacille de Calmette et Guérin (BCG) inoculation or nontuberculous mycobacteria, it has a higher specificity than the tuberculin reaction. There are two kinds of IRGA, QuantiFERON TB and T Spot , and it was reported that the sensitivity was reduced to a lesser degree in the latter even when immunity was perturbed or immunosuppressants were administered because the number of lymphocytes was adjusted after separation (7) .
Some known adverse effects of IFN treatment include not only depression, pancytopenia, interstitial pneumonitis, and (11) . The induction of Tb in CHC cases by IFN treatment is not rare, and it has been speculated that a reduction in CD4-positive lymphocytes by IFN administration is one of the causes for the onset of Tb. To the best of our knowledge, combination therapy with PEG-IFN/RBV/telaprevir induced Tb in only one case that developed hemophagocytic syndrome according to the report by Rodríguez-Medina et al (12) . This may be because CD4-positive Th1 lymphocytes play an important role in the prevention of mycobacterial infection via secretion of IFNγ and tumor necrosis factor (TNF)-α (8) . In the present case, CD4-positive lymphocytes in the peripheral blood were not counted, however, the total lymphocyte count in the peripheral blood decreased to 1,058/μL on admission and to 770/μL on day 14, which suggested that CD4-positive lymphocytes were also decreased, leading to the induction of Tb. It was presumed that telaprevir was not the cause, but had instead had caused a decrease in cellular immunity by PEG-IFN therapy (8) .
Liver histology before treatment showed IR with bridging fibrosis corresponding to F2. IR was reported by Shibata and Uchida in 1998 (13) , and CHC cases with severe IR are prone to develop cancer in the future. Thereafter, Matsumura and Moriyama et al. classified the degree of IR into five grades and reported that the rate of cancer development was high in advanced fibrosis cases (F3 + F4) with atypical hepatocytes, a characteristic of IR (14) .
In the present case, a population of small atypical hepatocytes was detected in the collected tissue sample. In addition, two ECGs were also observed in the tissue. Granuloma is a nodular lesion characterized by the accumulation of epithelioid cells derived from macrophages, which is considered to be a protective reaction of the host against external antigens. Two types of granulomas are observed in the liver: ECG and lipogranulomata (15) . The former often forms a clear cluster and is observed in primary biliary cirrhosis (PBC), Tb, and sarcoidosis, while the latter is often detected in nonalcoholic fatty liver disease as an in vivo reaction to fat droplets.
ECGs are observed in 1 -10% of CHC cases (15, 16) . Since a liver biopsy was carried out in a total of 376 cases between January 2007 and December 2014 at Nihon Univer- the lung hilum is often observed, however, this was not in the present case. Pathologically, even though ECGs were observed in the liver parenchyma, it was impossible to rule out PBC. However, since neither chronic non-suppurative destructive cholangitis (CNSDC) nor disappearance of the bile ducts was observed in the portal areas in the specimen, and copper-binding protein was not detected by orcein staining, the pathological findings were compatible with CHC infection in the present case.
With regard to Tb, although other diseases were unlikely, a definitive diagnosis of Tb could not be achieved due to the absence of caseous necrosis and negative Ziehl-Nielsen staining, but a positive T-spot result was a key for the diagnosis. Drebber et al. examined 12,161 cases by liver biopsies and detected ECGs (excluding lipogranulomata) in 442 cases (3.63%), approximately half (48.6%) of which were diagnosed with PBC (18) . In addition, infectious disease including Tb was diagnosed by PCR using formaldehyde-fixed paraffin-embedded specimens, and three cases were diagnosed with PBC. Such investigation is necessary in the present case, which we would like to attempt in the future.
An earlier report showed that previous treatment with IFNα induced ECGs (17) , which was a possibility in the present case. When ECGs are observed in the liver tissue before IFN treatment, other diseases must be investigated, while the tuberculin reaction, T-spot, sputum and gastric juice cultures, and PCR must be performed in advance. When Tb is suspected, it is necessary to fully inform the patient with regard to the potential of Tb induction from a LTBI by IFN treatment.
In addition, it is necessary to monitor the fever pattern and repeat chest X-ray examinations during treatment. Interestingly, Babudieri et al. showed that a LTBI was often detected in HCV-infected patients and reported that lung Tb developed 33 weeks after PEG-IFN/RBV treatment in prisoner patients without a history of Tb (19) . They also reported that a detailed clinical history, examination by the tuberculin reaction and QuantiFERON, and intensive followup by X-ray examinations were necessary before IFN treatment.
Although the frequency of IFN administration has decreased, the long-term prognosis after DAA treatment and prevention of carcinogenesis in CHC cases remain unclarified at present, and the significance of IFN may be reviewed. Moreover, since IFN therapy is also administered for CHB infection and malignant tumors, clinicians need to fully understand the adverse effects and events associated with this treatment.
The present case suggested that a liver biopsy before the introduction of IFN treatment is important. Abundant information can be obtained from one liver biopsy specimen and when ECGs (in particular, cluster formation) are detected, it is necessary to review the clinical course and make a diagnosis with as much knowledge as possible.
The authors state that they have no Conflict of Interest (COI).

